<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01075152</url>
  </required_header>
  <id_info>
    <org_study_id>DAIDS-ES ID 10795</org_study_id>
    <secondary_id>U01AI089244</secondary_id>
    <nct_id>NCT01075152</nct_id>
  </id_info>
  <brief_title>Cryptococcal Optimal ART Timing Trial</brief_title>
  <acronym>COAT</acronym>
  <official_title>Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mbarara University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal
      meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital
      discharge results in superior survival compared to standard initiation of ART started as an
      outpatient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After 7-11 days of amphotericin B therapy, subjects will be randomized in a 1:1 allocation
      to:

        -  Early initiation of ART (Experimental Group) = ART initiated within 48 hours after study
           entry, OR

        -  Standard initiation of ART (Control Group) = ART at &gt;=4 weeks after study entry

      HIV therapy will be with efavirenz plus nucleoside backbone per national guidelines for first
      line therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>26 weeks from study entry</time_frame>
    <description>Intention to treat analysis of 26 week survival of all subjects enrolled. Reported below are the numbers of participants who died by Week 26.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Immune Reconstitution Inflammatory Syndrome</measure>
    <time_frame>46 weeks</time_frame>
    <description>Incidence of cryptococcal-related immune reconstitution inflammatory syndrome through 46 weeks after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cryptococcal-relapse</measure>
    <time_frame>46 weeks</time_frame>
    <description>Incidence of culture positive cryptococcal meningitis relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of ART Initiation</measure>
    <time_frame>46 weeks</time_frame>
    <description>Incidence of Adverse Events (Grade 3,4,5) through 46-weeks, as defined by the National Institute of Allergy and Infectious Diseases, Division of AIDS toxicity classification scale, version 2009.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>46-week Survival</measure>
    <time_frame>46 weeks</time_frame>
    <description>46-week survival by time-to-event analysis of all subjects enrolled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 Viral Suppression</measure>
    <time_frame>26 weeks</time_frame>
    <description>HIV-1 virologic suppression to &lt;400 copies/mL at 26-weeks after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral Therapy Tolerability</measure>
    <time_frame>26 weeks</time_frame>
    <description>Incidence of antiretroviral therapy interruption by &gt;=3 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Functional Status</measure>
    <time_frame>46 weeks</time_frame>
    <description>Functional status via Karnofsky performance status score at 4, 26, 46 weeks.
Karnofsky Scale:
100 - Normal; no complaints; no evidence of disease. 90 - Able to carry on normal activity; minor signs or symptoms of disease. 80 - Normal activity with effort; some signs or symptoms of disease. 70 - Cares for self; unable to carry on normal activity or to do active work. 60 - Requires occasional assistance, but is able to care for most of his personal needs.
50 - Requires considerable assistance and frequent medical care. 40 - Disabled; requires special care and assistance. 30 - Severely disabled; hospital admission is indicated although death not imminent.
20 - Very sick; hospital admission necessary; active supportive treatment necessary.
10 - Moribund; fatal processes progressing rapidly. 0 - Dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic Clearance</measure>
    <time_frame>4 weeks</time_frame>
    <description>Microbiologic clearance of cryptococcus as measured by serial quantitative cryptococcal cultures collected at diagnosis through 14 days of amphotericin therapy. The early fungicidal activity (EFA) of the rate of clearance is expressed as log10 colony forming units (CFU) of Cryptococcus neoformans per mL of CSF per day.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants, Per CSF WBC Subgroup, Who Died by Week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of Participants who died by week 26 based on CSF white blood cell (WBC) count at study entry (time of randomization at a median of 8 days of anti-fungal therapy).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Earlier HIV Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV therapy initiated at 7-13 days of cryptococcal meningitis diagnosis. HIV therapy consisting of a nucleoside with lamivudine and efavirenz.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred HIV Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis diagnosis (+/- 1 week).
HIV therapy consisting of a nucleoside with lamivudine and efavirenz.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.</description>
    <arm_group_label>Earlier HIV Therapy</arm_group_label>
    <arm_group_label>Deferred HIV Therapy</arm_group_label>
    <other_name>sustiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nucleoside</intervention_name>
    <description>Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.</description>
    <arm_group_label>Earlier HIV Therapy</arm_group_label>
    <arm_group_label>Deferred HIV Therapy</arm_group_label>
    <other_name>zidovudine or stavudine</other_name>
    <other_name>lamivudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infection, documented by ELISA

          -  Antiretroviral medication naïve (excluding mother-to-child transmission therapy)

          -  Age &gt;14 years

          -  Cryptococcal meningitis diagnosed by either culture or CSF cryptococcal antigen (CRAG)

          -  Ability and willingness of the participant or legal guardian/representative to give
             informed consent.

          -  Receiving amphotericin-based anti-fungal therapy

        Exclusion Criteria:

          -  Study entry prior to receipt of &lt;7 days or &gt;11 days of amphotericin therapy

          -  History of prior, known cryptococcal meningitis

          -  Inability to take enteral medication

          -  Receiving chemotherapy or other immunosuppressant medications

          -  Cannot or unlikely to attend regular clinic visits

          -  Contraindication to immediate or delayed HIV therapy based on serious co-morbidities
             or co-infections, or laboratory values

          -  Pregnancy or Breastfeeding

          -  Female participants of childbearing potential who are participating in sexual activity
             that could lead to pregnancy must agree to use two reliable methods of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Boulware, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GF Jooste Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Institute, Mulago Hospital, Makerere University</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mbarara University of Science and Technology</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1056/NEJMoa1312884</url>
    <description>N Engl J Med 2014 - Final Results</description>
  </link>
  <reference>
    <citation>Rajasingham R, Williams D, Meya DB, Meintjes G, Boulware DR, Scriven J. Nosocomial drug-resistant bacteremia in 2 cohorts with cryptococcal meningitis, Africa. Emerg Infect Dis. 2014 Apr;20(4):722-4. doi: 10.3201/eid2004.131277.</citation>
    <PMID>24655747</PMID>
  </reference>
  <reference>
    <citation>Carlson RD, Rolfes MA, Birkenkamp KE, Nakasujja N, Rajasingham R, Meya DB, Boulware DR. Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. Metab Brain Dis. 2014 Jun;29(2):269-279. doi: 10.1007/s11011-013-9476-1. Epub 2014 Jan 9.</citation>
    <PMID>24399496</PMID>
  </reference>
  <reference>
    <citation>Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, Taseera K, Schutz C, Kwizera R, Butler EK, Meintjes G, Muzoora C, Bischof JC, Meya DB. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis. 2014 Jan;20(1):45-53. doi: 10.3201/eid2001.130906.</citation>
    <PMID>24378231</PMID>
  </reference>
  <reference>
    <citation>Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis. 2014 Jan;58(1):113-6. doi: 10.1093/cid/cit641. Epub 2013 Sep 24.</citation>
    <PMID>24065327</PMID>
  </reference>
  <reference>
    <citation>Robertson EJ, Najjuka G, Rolfes MA, Akampurira A, Jain N, Anantharanjit J, von Hohenberg M, Tassieri M, Carlsson A, Meya DB, Harrison TS, Fries BC, Boulware DR, Bicanic T. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis. 2014 Jan 1;209(1):74-82. doi: 10.1093/infdis/jit435. Epub 2013 Aug 14.</citation>
    <PMID>23945372</PMID>
  </reference>
  <reference>
    <citation>Durski KN, Kuntz KM, Yasukawa K, Virnig BA, Meya DB, Boulware DR. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):e101-8. doi: 10.1097/QAI.0b013e31828e1e56.</citation>
    <PMID>23466647</PMID>
  </reference>
  <reference>
    <citation>Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med. 2012;9(9):e1001316. doi: 10.1371/journal.pmed.1001316. Epub 2012 Sep 25.</citation>
    <PMID>23055838</PMID>
  </reference>
  <reference>
    <citation>Rolfes MA, Hullsiek KH, Rhein J, Nabeta HW, Taseera K, Schutz C, Musubire A, Rajasingham R, Williams DA, Thienemann F, Muzoora C, Meintjes G, Meya DB, Boulware DR. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis. 2014 Dec 1;59(11):1607-14. doi: 10.1093/cid/ciu596. Epub 2014 Jul 23. Erratum in: Clin Infect Dis. 2015 May 1;60(9):1449.</citation>
    <PMID>25057102</PMID>
  </reference>
  <reference>
    <citation>Scriven JE, Rhein J, Hullsiek KH, von Hohenberg M, Linder G, Rolfes MA, Williams DA, Taseera K, Meya DB, Meintjes G, Boulware DR; COAT Team. Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial. J Infect Dis. 2015 Sep 1;212(5):769-78. doi: 10.1093/infdis/jiv067. Epub 2015 Feb 4.</citation>
    <PMID>25651842</PMID>
  </reference>
  <reference>
    <citation>Williams DA, Kiiza T, Kwizera R, Kiggundu R, Velamakanni S, Meya DB, Rhein J, Boulware DR. Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study. Clin Infect Dis. 2015 Aug 1;61(3):464-7. doi: 10.1093/cid/civ263. Epub 2015 Apr 1.</citation>
    <PMID>25838287</PMID>
  </reference>
  <reference>
    <citation>Rajasingham R, Rhein J, Klammer K, Musubire A, Nabeta H, Akampurira A, Mossel EC, Williams DA, Boxrud DJ, Crabtree MB, Miller BR, Rolfes MA, Tengsupakul S, Andama AO, Meya DB, Boulware DR. Epidemiology of meningitis in an HIV-infected Ugandan cohort. Am J Trop Med Hyg. 2015 Feb;92(2):274-9. doi: 10.4269/ajtmh.14-0452. Epub 2014 Nov 10.</citation>
    <PMID>25385864</PMID>
  </reference>
  <reference>
    <citation>Nabeta HW, Bahr NC, Rhein J, Fossland N, Kiragga AN, Meya DB, Dunlop SJ, Boulware DR. Accuracy of noninvasive intraocular pressure or optic nerve sheath diameter measurements for predicting elevated intracranial pressure in cryptococcal meningitis. Open Forum Infect Dis. 2014 Oct 11;1(3):ofu093. doi: 10.1093/ofid/ofu093. eCollection 2014 Dec.</citation>
    <PMID>25734161</PMID>
  </reference>
  <reference>
    <citation>Meya DB, Okurut S, Zziwa G, Rolfes MA, Kelsey M, Cose S, Joloba M, Naluyima P, Palmer BE, Kambugu A, Mayanja-Kizza H, Bohjanen PR, Eller MA, Wahl SM, Boulware DR, Manabe YC, Janoff EN. Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. J Infect Dis. 2015 May 15;211(10):1597-606. doi: 10.1093/infdis/jiu664. Epub 2014 Dec 9.</citation>
    <PMID>25492918</PMID>
  </reference>
  <reference>
    <citation>Bahr NC, Rolfes MA, Musubire A, Nabeta H, Williams DA, Rhein J, Kambugu A, Meya DB, Boulware DR. Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings. Open Forum Infect Dis. 2014 Aug 25;1(2):ofu070. doi: 10.1093/ofid/ofu070. eCollection 2014 Sep.</citation>
    <PMID>25734140</PMID>
  </reference>
  <reference>
    <citation>Kwizera R, Nguna J, Kiragga A, Nakavuma J, Rajasingham R, Boulware DR, Meya DB. Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 &lt;100. PLoS One. 2014 Jul 31;9(7):e103156. doi: 10.1371/journal.pone.0103156. eCollection 2014.</citation>
    <PMID>25078453</PMID>
  </reference>
  <results_reference>
    <citation>Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, Taseera K, Nabeta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G; COAT Trial Team. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014 Jun 26;370(26):2487-98. doi: 10.1056/NEJMoa1312884.</citation>
    <PMID>24963568</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <results_first_submitted>June 27, 2014</results_first_submitted>
  <results_first_submitted_qc>July 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2014</results_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cryptococcal meningitis</keyword>
  <keyword>cryptococcus</keyword>
  <keyword>cryptococcosis</keyword>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Earlier HIV Therapy</title>
          <description>HIV therapy initiated at 7-13 days after cryptococcal diagnosis</description>
        </group>
        <group group_id="P2">
          <title>Deferred HIV Therapy</title>
          <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis diagnosis (+/1 week)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88">randomized</participants>
                <participants group_id="P2" count="89">randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>HIV-infected persons not previously receiving HIV therapy with first episode of cryptococcal meningitis diagnosed by CSF culture and/or CSF cryptococcal antigen testing.</population>
      <group_list>
        <group group_id="B1">
          <title>Earlier HIV Therapy</title>
          <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis.</description>
        </group>
        <group group_id="B2">
          <title>Deferred HIV Therapy</title>
          <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis diagnosis (+/- 1 week)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="177"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="28" upper_limit="40"/>
                    <measurement group_id="B2" value="36" lower_limit="30" upper_limit="40"/>
                    <measurement group_id="B3" value="35" lower_limit="29" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Count, baseline</title>
          <units>cells/mcL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" lower_limit="9" upper_limit="69"/>
                    <measurement group_id="B2" value="28" lower_limit="11" upper_limit="76"/>
                    <measurement group_id="B3" value="23" lower_limit="10" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF Quantitative Culture, baseline</title>
          <units>log10 colony forming units/mL of CSF</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" lower_limit="4.2" upper_limit="5.7"/>
                    <measurement group_id="B2" value="4.8" lower_limit="3.8" upper_limit="5.5"/>
                    <measurement group_id="B3" value="5.1" lower_limit="4.0" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF Cryptococcal Antigen titer, 1:xxxx</title>
          <description>as performed by serial dilutions with lateral flow assay (LFA)</description>
          <units>titers</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8000" lower_limit="2000" upper_limit="16000"/>
                    <measurement group_id="B2" value="4000" lower_limit="1000" upper_limit="14400"/>
                    <measurement group_id="B3" value="6400" lower_limit="2000" upper_limit="16000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 Viral Load</title>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" lower_limit="5.2" upper_limit="5.8"/>
                    <measurement group_id="B2" value="5.5" lower_limit="5.3" upper_limit="5.8"/>
                    <measurement group_id="B3" value="5.5" lower_limit="5.2" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mortality</title>
        <description>Intention to treat analysis of 26 week survival of all subjects enrolled. Reported below are the numbers of participants who died by Week 26.</description>
        <time_frame>26 weeks from study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week).</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Intention to treat analysis of 26 week survival of all subjects enrolled. Reported below are the numbers of participants who died by Week 26.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We compared the randomization arms for the primary endpoint of survival using time-to-event methods of Cox proportional hazards models by the intention-to-treat principle, based on two-sided type-I error with alpha=0.05.
The trial was statistically powered to detect a 25% relative survival benefit (15% absolute benefit) with 90% power and overall two-sided alpha=0.05 with an intended sample size of 500 participants. The trial was halted early by the Data and Safety Monitoring Board.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>A Lan-DeMets spending function analog of the O’Brien-Fleming boundaries was proposed to control the type-I error resulting from multiple interim analyses.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
            <estimate_desc>Hazard Ratio describes the risk of earlier HIV therapy in comparison to deferred HIV therapy initiation as the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Immune Reconstitution Inflammatory Syndrome</title>
        <description>Incidence of cryptococcal-related immune reconstitution inflammatory syndrome through 46 weeks after enrollment.</description>
        <time_frame>46 weeks</time_frame>
        <population>analysis is of persons who survived to initiate HIV therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Immune Reconstitution Inflammatory Syndrome</title>
          <description>Incidence of cryptococcal-related immune reconstitution inflammatory syndrome through 46 weeks after enrollment.</description>
          <population>analysis is of persons who survived to initiate HIV therapy</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To account for the competing risk of death, the cumulative incidence function compared the randomized groups for endpoints of IRIS, relapse, and adverse events (Gray's method).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Gray's method of cumulative incidence</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Cryptococcal-relapse</title>
        <description>Incidence of culture positive cryptococcal meningitis relapse</description>
        <time_frame>46 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cryptococcal-relapse</title>
          <description>Incidence of culture positive cryptococcal meningitis relapse</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To account for the competing risk of death, the cumulative incidence function compared the randomized groups for endpoints of IRIS, relapse, and adverse events (Gray's method).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Gray's method of cumulative incidence</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of ART Initiation</title>
        <description>Incidence of Adverse Events (Grade 3,4,5) through 46-weeks, as defined by the National Institute of Allergy and Infectious Diseases, Division of AIDS toxicity classification scale, version 2009.</description>
        <time_frame>46 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of ART Initiation</title>
          <description>Incidence of Adverse Events (Grade 3,4,5) through 46-weeks, as defined by the National Institute of Allergy and Infectious Diseases, Division of AIDS toxicity classification scale, version 2009.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Categorical secondary endpoints were compared with Fisher’s exact tests.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>46-week Survival</title>
        <description>46-week survival by time-to-event analysis of all subjects enrolled</description>
        <time_frame>46 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
          </group>
        </group_list>
        <measure>
          <title>46-week Survival</title>
          <description>46-week survival by time-to-event analysis of all subjects enrolled</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We compared the randomization arms for survival using time-to-event methods of Cox proportional hazards models.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 Viral Suppression</title>
        <description>HIV-1 virologic suppression to &lt;400 copies/mL at 26-weeks after enrollment</description>
        <time_frame>26 weeks</time_frame>
        <population>Among persons alive at 26 weeks. 1 participant in the early ART arm had consent withdrawn by their family on day 2 after study entry. 3 participants in the deferred ART arm missing their 26 week viral load sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Viral Suppression</title>
          <description>HIV-1 virologic suppression to &lt;400 copies/mL at 26-weeks after enrollment</description>
          <population>Among persons alive at 26 weeks. 1 participant in the early ART arm had consent withdrawn by their family on day 2 after study entry. 3 participants in the deferred ART arm missing their 26 week viral load sampling.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Categorical secondary endpoints were compared with Fisher’s exact tests.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antiretroviral Therapy Tolerability</title>
        <description>Incidence of antiretroviral therapy interruption by &gt;=3 consecutive days</description>
        <time_frame>26 weeks</time_frame>
        <population>Analysis is of persons who survived to initiate HIV therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis]</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Antiretroviral Therapy Tolerability</title>
          <description>Incidence of antiretroviral therapy interruption by &gt;=3 consecutive days</description>
          <population>Analysis is of persons who survived to initiate HIV therapy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Categorical secondary endpoints were compared with Fisher’s exact tests.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Karnofsky Functional Status</title>
        <description>Functional status via Karnofsky performance status score at 4, 26, 46 weeks.
Karnofsky Scale:
100 - Normal; no complaints; no evidence of disease. 90 - Able to carry on normal activity; minor signs or symptoms of disease. 80 - Normal activity with effort; some signs or symptoms of disease. 70 - Cares for self; unable to carry on normal activity or to do active work. 60 - Requires occasional assistance, but is able to care for most of his personal needs.
50 - Requires considerable assistance and frequent medical care. 40 - Disabled; requires special care and assistance. 30 - Severely disabled; hospital admission is indicated although death not imminent.
20 - Very sick; hospital admission necessary; active supportive treatment necessary.
10 - Moribund; fatal processes progressing rapidly. 0 - Dead</description>
        <time_frame>46 weeks</time_frame>
        <population>Analysis is of persons alive at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Karnofsky Functional Status</title>
          <description>Functional status via Karnofsky performance status score at 4, 26, 46 weeks.
Karnofsky Scale:
100 - Normal; no complaints; no evidence of disease. 90 - Able to carry on normal activity; minor signs or symptoms of disease. 80 - Normal activity with effort; some signs or symptoms of disease. 70 - Cares for self; unable to carry on normal activity or to do active work. 60 - Requires occasional assistance, but is able to care for most of his personal needs.
50 - Requires considerable assistance and frequent medical care. 40 - Disabled; requires special care and assistance. 30 - Severely disabled; hospital admission is indicated although death not imminent.
20 - Very sick; hospital admission necessary; active supportive treatment necessary.
10 - Moribund; fatal processes progressing rapidly. 0 - Dead</description>
          <population>Analysis is of persons alive at the time point.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="19"/>
                    <measurement group_id="O2" value="70" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" spread="7"/>
                    <measurement group_id="O2" value="93" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>46 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="10"/>
                    <measurement group_id="O2" value="95" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The overall change from baseline in Karnofsky performance status scores was compared between groups via a repeated measure analysis, unstructured covariance matrix, adjusted for baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>repeated measure analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiologic Clearance</title>
        <description>Microbiologic clearance of cryptococcus as measured by serial quantitative cryptococcal cultures collected at diagnosis through 14 days of amphotericin therapy. The early fungicidal activity (EFA) of the rate of clearance is expressed as log10 colony forming units (CFU) of Cryptococcus neoformans per mL of CSF per day.</description>
        <time_frame>4 weeks</time_frame>
        <population>All participants with &gt;2 quantitative CSF cultures obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiologic Clearance</title>
          <description>Microbiologic clearance of cryptococcus as measured by serial quantitative cryptococcal cultures collected at diagnosis through 14 days of amphotericin therapy. The early fungicidal activity (EFA) of the rate of clearance is expressed as log10 colony forming units (CFU) of Cryptococcus neoformans per mL of CSF per day.</description>
          <population>All participants with &gt;2 quantitative CSF cultures obtained</population>
          <units>log10 CFU/mL/day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EFA by mixed effects model</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" lower_limit="-0.34" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.31" lower_limit="-0.34" upper_limit="-0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFA by linear regression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" lower_limit="-0.45" upper_limit="-0.32"/>
                    <measurement group_id="O2" value="-0.35" lower_limit="-0.39" upper_limit="-0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To describe early fungicidal activity, a linear mixed effects regression model fit with a random intercept and slope estimated the rate of clearance of log10 colony forming units (CFU) of Cryptococcus, per mL of CSF per day, for all participants with &gt;2 cultures obtained.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Regression, Linear</method>
            <method_desc>a linear mixed effects regression model fit with a random intercept and slope estimated the rate of clearance</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants, Per CSF WBC Subgroup, Who Died by Week 26</title>
        <description>Percentage of Participants who died by week 26 based on CSF white blood cell (WBC) count at study entry (time of randomization at a median of 8 days of anti-fungal therapy).</description>
        <time_frame>26 weeks</time_frame>
        <population>among persons with a measured CSF white cell count at randomization (Day 7-11 of amphotericin treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Earlier HIV Therapy</title>
            <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
          </group>
          <group group_id="O2">
            <title>Deferred HIV Therapy</title>
            <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants, Per CSF WBC Subgroup, Who Died by Week 26</title>
          <description>Percentage of Participants who died by week 26 based on CSF white blood cell (WBC) count at study entry (time of randomization at a median of 8 days of anti-fungal therapy).</description>
          <population>among persons with a measured CSF white cell count at randomization (Day 7-11 of amphotericin treatment)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSF WBC &lt;5 /mcl (n=33, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                    <measurement group_id="O2" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSF WBC &gt;5/mcL (n=42, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre-specified subgroups formed by baseline characteristics were compared for 26 week survival with models including an interaction term between treatment arm and subgroup.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>This is the interaction p-value for CSF white cell count at randomization (implying there is a statistical difference in the outcome by arm based on this parameter).</p_value_desc>
            <method>Regression, Cox</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>46 weeks</time_frame>
      <desc>Grade 3,4,5 adverse events were protocol specified secondary endpoint and were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Earlier HIV Therapy</title>
          <description>HIV therapy initiated at 7-13 days after cryptococcal meningitis diagnosis</description>
        </group>
        <group group_id="E2">
          <title>Deferred HIV Therapy</title>
          <description>HIV therapy initiated at 5 weeks after cryptococcal meningitis (+/- 1 week)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>DAIDS Toxicity Table</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 5 AEs</sub_title>
                <description>Death
(The number of AEs is greater than the number of persons as multiple AEs could occur simultaneously in the same participant).</description>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Grade 4 Serious AEs</sub_title>
                <description>Initial Grade 4 serious AEs</description>
                <counts group_id="E1" events="59" subjects_affected="38" subjects_at_risk="88"/>
                <counts group_id="E2" events="57" subjects_affected="42" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Grade 3 Serious AEs</sub_title>
                <description>Grade 3-5 serious AEs</description>
                <counts group_id="E1" events="48" subjects_affected="40" subjects_at_risk="88"/>
                <counts group_id="E2" events="47" subjects_affected="38" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>DAIDS Toxicity Table</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematology</sub_title>
                <counts group_id="E1" events="99" subjects_affected="41" subjects_at_risk="88"/>
                <counts group_id="E2" events="128" subjects_affected="47" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E2" events="26" subjects_affected="18" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Chemistries</sub_title>
                <counts group_id="E1" events="65" subjects_affected="32" subjects_at_risk="88"/>
                <counts group_id="E2" events="53" subjects_affected="25" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The differences in mortality in the two arms were of sufficient magnitude that trial enrollment was stopped early by the Data and Safety Monitoring Board. Historically, trials stopped early routinely over-estimate the magnitude of benefit or harm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. David R Boulware</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>6126249996</phone>
      <email>boulw001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

